Are you currently dealing with Shingles?
Did you know that there may be a link between people with immunosuppression diseases like Shingles and a specific genetic mutation called the KRAS-variant?
The KRAS-variant has been shown to predict increased cancer risk, which can be modified by certain lifestyle and behavioral factors.
You may be eligible for one of several studies about the KRAS-variant, which seek to find the best ways to identify the link between these disorders and the KRAS-variant mutation.
What we know about the KRAS-variant:
- May have a link with immunosuppression
- Found in 6-10% of the population.
- Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies.
- Associated with advanced endometriosis and infertility.
The KRAS-variant is one of the most frequently identified inherited genetic markers associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.